[Chronic lymphocytic leukemia. 2. Therapy].
Hallek
M
M
Medizinische Klinik III, Ludwig-Maximilians-Universität München, Grosshadern.
Schmitt
B
B
Emmerich
B
B
Stein
H
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D012307:Risk Factors; D013156:Splenectomy; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D013256:Steroids; D002699:Chlorambucil; D014740:Vidarabine; C024352:fludarabine